This is a Phase 1 dose-escalation study of PRT3789, a SMARCA2 degrader, in participantswith advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutationand/or deletion. The purpose of this study is to evaluate the safety, tolerability,pharmacokinetic (PK), and pharmacodynamic (PD) of PRT3789 monotherapy and in combinationwith docetaxel, describe any dose limiting toxicities (DLTs), define the dosing schedule,and to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) tobe used in subsequent development of PRT3789.
This is a Phase 1 dose-escalation study of PRT3789, a SMARCA2 degrader, in participantswith advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutationand/or deletion. The purpose of this study is to evaluate the safety, tolerability,pharmacokinetic (PK), and pharmacodynamic (PD) of PRT3789 monotherapy and in combinationwith docetaxel, describe any dose limiting toxicities (DLTs), define the dosing schedule,and to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) tobe used in subsequent development of PRT3789.
